blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2805951

EP2805951 - Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.01.2019
Database last updated on 12.07.2024
FormerThe patent has been granted
Status updated on  09.02.2018
FormerGrant of patent is intended
Status updated on  06.09.2017
FormerExamination is in progress
Status updated on  02.12.2016
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Metabasis Therapeutics, Inc.
3911 Sorrento Valley Boulevard, Suite 110
San Diego, CA 92121 / US
[2018/10]
Former [2014/48]For all designated states
Metabasis Therapeutics, Inc.
11119 North Torrey Pines Road, Suite 200
La Jolla, CA 92037 / US
Inventor(s)01 / Reddy, K. Raja
5507 Mill Creek Rd
San Diego, CA California 92130 / US
02 / Stebbins, Jeff
3922 Hamilton St.
Unit 4
San Diego, CA California 92014 / US
03 / Boyer, Serge, H.
5112 Castle Hills Drive
San Diego, CA California 92109 / US
04 / Erion, Mark, D.
13455 Mango Drive
Del Mar, CA California 92014 / US
05 / Hecker, Scott, J.
4802 Rancho Viejo Drive
Del Mar, CA California 92014 / US
06 / Raffaele, Nicholas, Brian
2606 Illion St.
San Diego, CA California 92110 / US
07 / Bookser, Brett, C.
4186 Sturgeon Court
San Diego, CA California 92130 / US
08 / Reddy, Mali, Venkat
10447 Whitecomb Way, Apt. 158
San Diego, CA California 92127 / US
 [2014/48]
Representative(s)Gallois, Valérie, et al
Cabinet Becker & Associés
25, rue Louis le Grand
75002 Paris / FR
[2014/48]
Application number, filing date14172611.719.03.2010
[2014/48]
Priority number, dateUS20090162170P20.03.2009         Original published format: US 162170 P
[2014/48]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2805951
Date:26.11.2014
Language:EN
[2014/48]
Type: A3 Search report 
No.:EP2805951
Date:29.04.2015
Language:EN
[2015/18]
Type: B1 Patent specification 
No.:EP2805951
Date:14.03.2018
Language:EN
[2018/11]
Search report(s)(Supplementary) European search report - dispatched on:EP30.03.2015
ClassificationIPC:C07D473/16, C07D473/34, C07D473/40, C07F9/30, C07F9/32, C07F9/653, C07F9/6561, C07F9/6574, A61K31/52, A61K31/662, A61K31/665, A61K31/675, A61P3/10, A61P3/04, A61K45/06, A61K31/542, A61K31/683, A61K31/688
[2017/26]
CPC:
A61K31/675 (EP,US); A61K31/52 (EP,US); A61K31/542 (EP,US);
A61K31/662 (EP,US); A61K31/665 (EP,US); A61K31/683 (EP,US);
A61K31/688 (EP,US); A61K45/06 (EP,US); A61P3/04 (EP,US);
A61P3/10 (EP,US); C07D473/16 (EP,US); C07D473/34 (EP,US);
C07D473/40 (EP,US); C07F9/303 (EP,US); C07F9/3229 (EP,US);
C07F9/40 (US); C07F9/48 (US); C07F9/65312 (EP,US);
C07F9/6552 (US); C07F9/6561 (EP,US); C07F9/65616 (EP,US);
C07F9/65742 (EP,US) (-)
C-Set:
A61K31/52, A61K2300/00 (EP,US);
A61K31/662, A61K2300/00 (US,EP);
A61K31/665, A61K2300/00 (US,EP);
A61K31/675, A61K2300/00 (US,EP)
Former IPC [2014/48]C07D473/16, C07D473/34, C07D473/40, C07F9/30, C07F9/32, C07F9/653, C07F9/6561, C07F9/6574, A61K31/52, A61K31/662, A61K31/665, A61K31/675, A61P3/10, A61P3/04, A61K45/06
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2015/49]
Former [2014/48]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
TitleGerman:Inhibitoren von Diacylglycerin-O-acyltransferase 1 (DGAT-1) und Verwendungen davon[2014/48]
English:Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof[2014/48]
French:Inhibiteurs de diacylglycérol o-acétyltransférase 1 (dgat-1) et leurs utilisations[2014/48]
Examination procedure27.10.2015Amendment by applicant (claims and/or description)
27.10.2015Examination requested  [2015/49]
12.11.2015Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time
30.11.2016Despatch of a communication from the examining division (Time limit: M02)
27.01.2017Reply to a communication from the examining division
21.03.2017Despatch of a communication from the examining division (Time limit: M02)
11.05.2017Reply to a communication from the examining division
07.09.2017Communication of intention to grant the patent
17.01.2018Fee for grant paid
17.01.2018Fee for publishing/printing paid
17.01.2018Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP10710137.0  / EP2408774
Divisional application(s)EP18150958.9  / EP3366686
Opposition(s)17.12.2018No opposition filed within time limit [2019/08]
Fees paidRenewal fee
16.06.2014Renewal fee patent year 03
16.06.2014Renewal fee patent year 04
16.06.2014Renewal fee patent year 05
30.09.2015Renewal fee patent year 06
18.11.2016Renewal fee patent year 07
10.03.2017Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.03.201506   M06   Fee paid on   30.09.2015
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.03.2010
AT14.03.2018
CY14.03.2018
CZ14.03.2018
DK14.03.2018
EE14.03.2018
ES14.03.2018
FI14.03.2018
HR14.03.2018
IT14.03.2018
LT14.03.2018
LV14.03.2018
MC14.03.2018
MK14.03.2018
NL14.03.2018
PL14.03.2018
RO14.03.2018
SE14.03.2018
SI14.03.2018
SK14.03.2018
SM14.03.2018
TR14.03.2018
IE19.03.2018
LU19.03.2018
MT19.03.2018
BE31.03.2018
CH31.03.2018
LI31.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
IS14.07.2018
PT16.07.2018
[2020/33]
Former [2020/31]HU19.03.2010
AT14.03.2018
CY14.03.2018
CZ14.03.2018
DK14.03.2018
EE14.03.2018
ES14.03.2018
FI14.03.2018
HR14.03.2018
IT14.03.2018
LT14.03.2018
LV14.03.2018
MC14.03.2018
MK14.03.2018
NL14.03.2018
PL14.03.2018
RO14.03.2018
SE14.03.2018
SI14.03.2018
SK14.03.2018
SM14.03.2018
TR14.03.2018
IE19.03.2018
LU19.03.2018
MT19.03.2018
BE31.03.2018
CH31.03.2018
LI31.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
PT16.07.2018
Former [2020/28]HU19.03.2010
AT14.03.2018
CY14.03.2018
CZ14.03.2018
DK14.03.2018
EE14.03.2018
ES14.03.2018
FI14.03.2018
HR14.03.2018
IT14.03.2018
LT14.03.2018
LV14.03.2018
MC14.03.2018
NL14.03.2018
PL14.03.2018
RO14.03.2018
SE14.03.2018
SI14.03.2018
SK14.03.2018
SM14.03.2018
TR14.03.2018
IE19.03.2018
LU19.03.2018
MT19.03.2018
BE31.03.2018
CH31.03.2018
LI31.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
PT16.07.2018
Former [2020/16]AT14.03.2018
CY14.03.2018
CZ14.03.2018
DK14.03.2018
EE14.03.2018
ES14.03.2018
FI14.03.2018
HR14.03.2018
IT14.03.2018
LT14.03.2018
LV14.03.2018
MC14.03.2018
NL14.03.2018
PL14.03.2018
RO14.03.2018
SE14.03.2018
SI14.03.2018
SK14.03.2018
SM14.03.2018
TR14.03.2018
IE19.03.2018
LU19.03.2018
MT19.03.2018
BE31.03.2018
CH31.03.2018
LI31.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
PT16.07.2018
Former [2020/08]AT14.03.2018
CY14.03.2018
CZ14.03.2018
DK14.03.2018
EE14.03.2018
ES14.03.2018
FI14.03.2018
HR14.03.2018
IT14.03.2018
LT14.03.2018
LV14.03.2018
MC14.03.2018
NL14.03.2018
PL14.03.2018
RO14.03.2018
SE14.03.2018
SI14.03.2018
SK14.03.2018
SM14.03.2018
IE19.03.2018
LU19.03.2018
MT19.03.2018
BE31.03.2018
CH31.03.2018
LI31.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
PT16.07.2018
Former [2019/12]AT14.03.2018
CY14.03.2018
CZ14.03.2018
DK14.03.2018
EE14.03.2018
ES14.03.2018
FI14.03.2018
HR14.03.2018
IT14.03.2018
LT14.03.2018
LV14.03.2018
MC14.03.2018
NL14.03.2018
PL14.03.2018
RO14.03.2018
SE14.03.2018
SI14.03.2018
SK14.03.2018
SM14.03.2018
IE19.03.2018
LU19.03.2018
BE31.03.2018
CH31.03.2018
LI31.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
PT16.07.2018
Former [2019/08]AT14.03.2018
CY14.03.2018
CZ14.03.2018
DK14.03.2018
EE14.03.2018
ES14.03.2018
FI14.03.2018
HR14.03.2018
IT14.03.2018
LT14.03.2018
LV14.03.2018
MC14.03.2018
NL14.03.2018
PL14.03.2018
RO14.03.2018
SE14.03.2018
SK14.03.2018
SM14.03.2018
IE19.03.2018
LU19.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
PT16.07.2018
Former [2019/06]AT14.03.2018
CY14.03.2018
CZ14.03.2018
EE14.03.2018
ES14.03.2018
FI14.03.2018
HR14.03.2018
IT14.03.2018
LT14.03.2018
LV14.03.2018
MC14.03.2018
NL14.03.2018
PL14.03.2018
RO14.03.2018
SE14.03.2018
SK14.03.2018
SM14.03.2018
LU19.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
PT16.07.2018
Former [2019/04]AT14.03.2018
CY14.03.2018
CZ14.03.2018
EE14.03.2018
ES14.03.2018
FI14.03.2018
HR14.03.2018
IT14.03.2018
LT14.03.2018
LV14.03.2018
NL14.03.2018
PL14.03.2018
RO14.03.2018
SE14.03.2018
SK14.03.2018
SM14.03.2018
LU19.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
PT16.07.2018
Former [2019/03]AT14.03.2018
CY14.03.2018
CZ14.03.2018
EE14.03.2018
ES14.03.2018
FI14.03.2018
HR14.03.2018
IT14.03.2018
LT14.03.2018
LV14.03.2018
NL14.03.2018
PL14.03.2018
RO14.03.2018
SE14.03.2018
SK14.03.2018
SM14.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
PT16.07.2018
Former [2018/52]AT14.03.2018
CY14.03.2018
CZ14.03.2018
EE14.03.2018
ES14.03.2018
FI14.03.2018
HR14.03.2018
IT14.03.2018
LT14.03.2018
LV14.03.2018
NL14.03.2018
PL14.03.2018
RO14.03.2018
SE14.03.2018
SK14.03.2018
SM14.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
Former [2018/50]AT14.03.2018
CY14.03.2018
CZ14.03.2018
EE14.03.2018
ES14.03.2018
FI14.03.2018
HR14.03.2018
IT14.03.2018
LT14.03.2018
LV14.03.2018
NL14.03.2018
PL14.03.2018
RO14.03.2018
SE14.03.2018
SK14.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
Former [2018/47]CY14.03.2018
ES14.03.2018
FI14.03.2018
HR14.03.2018
IT14.03.2018
LT14.03.2018
LV14.03.2018
NL14.03.2018
SE14.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
Former [2018/45]CY14.03.2018
FI14.03.2018
HR14.03.2018
LT14.03.2018
LV14.03.2018
NL14.03.2018
SE14.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
Former [2018/40]CY14.03.2018
FI14.03.2018
HR14.03.2018
LT14.03.2018
LV14.03.2018
SE14.03.2018
BG14.06.2018
NO14.06.2018
GR15.06.2018
Former [2018/37]CY14.03.2018
FI14.03.2018
HR14.03.2018
LT14.03.2018
NO14.06.2018
GR15.06.2018
Former [2018/35]CY14.03.2018
FI14.03.2018
HR14.03.2018
LT14.03.2018
NO14.06.2018
Documents cited:SearchWO2006023654  [ ] (UNIV COLUMBIA [US]);
 [AD]WO2006044775  (BAYER PHARMACEUTICALS CORP [US], et al) [AD] 1-5 * claims 1-31 * * paragraph [0151] - paragraph [0286] * * abstract *;
 [A]  - STURLEY, STEPHEN, L. ET AL, "awat-related compounds. for metabolic or sebaceous gland disorders", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (20060427), Database accession no. 2006:194188, URL: STN, XP002733266 [A] 1-5 * abstract *
by applicantUS6110903
 US6399782
 WO2004047755
 US6849476
 WO2005044250
 US6919322
 US6965033
 US6967193
 WO2006044775
 WO2006064189
 WO2006113919
 WO2006134317
 WO2007016538
 WO2007022073
 WO2007071966
 WO2007137103
 WO2007137107
 WO2007138304
 WO2007138311
 WO2007141502
 WO2007141517
 WO2007141538
 WO2007141545
 WO2007144571
 WO2008067257
 WO2008099221
 WO2008129319
 WO2008134690
 WO2008134693
 WO2009011285
 WO2009016462
    - The Practice ofMedicinal Chemistry, ACADEMIC PRESS, (1996), page 203
    - XU ET AL., J. ORG. CHEM., (1996), vol. 61, pages 7697 - 7701
    - MORISE ET AL., J. CHEM. SOC. PERKIN TRANS. I, (1996), pages 2179 - 2185
    - BENNETTE ET AL., J. CHEM. SOC. PERKIN TRANS. I, (1995), pages 1145 - 1151
    - KALEK ET AL., ORG. LETT., (2008), vol. 10, pages 637 - 4640
    - BONNAVENTURE ET AL., J. ORG. CHEM., (2008), vol. 73, pages 6330 - 6340
    - HUBBARD ET AL., BIOORG. MED. CHEM. LETT., (2008), vol. 18, pages 679 - 681
    - BOYD ET AL., TETRAHEDRON LETT., (1996), vol. 37, pages 5425 - 5426
    - ANDO ET AL., J ORG. CHEM., (1999), vol. 64, pages 8406 - 8408
    - PERUMAL ET AL., J ORG CHEM., (2006), vol. 71, pages 4778 - 4785
    - JACOBSEN ET AL., J. ORG. CHEM., (2006), vol. 71, pages 9183 - 9190
    - GREEN, TETRAHEDRON LETT., (1989), vol. 30, pages 4807 - 4810
    - ZHAO ET AL., J. MED. CHEM., (2008), vol. 51, pages 380 - 383
    - CHANDRASEKHAR ET AL., SYNLETT, (2003), vol. 4, pages 505 - 506
    - ORDONEZ ET AL., TETRAHEDRON, (2009), vol. 65, pages 17 - 49
    - MONZILLO ET AL., NUTRITION REVIEWS, (2003), vol. 61, no. 12, pages 397 - 412
    - BONORA ET AL., J CLIN ENDOCRINOL METAB., (1989), vol. 68, pages 374 - 378
    - BERGMAN, ENDOCRINE REVIEWS, (1985), vol. 6, pages 45 - 86
    - GUERRE-MILLO M ET AL., JBC, (2000), vol. 275, pages 16638 - 42
    - SCHUPP M ET AL., DIABETES, (2005), vol. 54, pages 3442 - 52
    - ARULMOZHI DK, (2008), vol. 60, no. 9, pages 1167 - 73
    - FUJI N. ET AL., DIABETES, (2008), vol. 57, pages 2958 - 66
    - FUNATO H ET AL., CELL METABOLISM, (2009), vol. 9, no. 1, pages 64 - 76
    - CHEN, H.C.; STONE, S.J.; ZHOU, P.; BUHMAN, K.K.; FARESE, R.V. JR., "Dissociation of obesity and impaired glucose disposal in mice overexpressing acyl coenzyme a:diacylglycerol acyltransferase 1 in white adipose tissue", DIABETES, (2002), vol. 51, no. 11, pages 3189 - 95
    - CHEN, H.C.; FARESE, R.V. JR., "Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGATI-deficient mice", ARTERIOSCLER THROMB VASC BIOL, (2005), vol. 25, no. 3, pages 482 - 6
    - HILL, J.O.; MELANSON, E.L.; WYATT, H.T., "Dietary fat intake and regulation of energy balance: implications for obesity", JNUTR, (2000), vol. 30, no. 2, pages 2845 - 2885
    - SHI, Y.; BURN, P., "Lipid metabolic enzymes: emerging drug targets for the treatment of obesity", NAT REV DRUG DISCOV, (2004), vol. 3, no. 8, pages 95 - 10
    - SMITH, S.J.; CASES, S.; JENSEN, D.R.; CHEN, H.C.; SANDE, E.; TOW, B.; SANAN, D.A.; RABER, J.; ECKEL, R.H.; FARESE, R.V. JR., "Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat", NAT GENET, (2000), vol. 25, no. 1, doi:doi:10.1038/75651, pages 87 - 90, XP002221994

DOI:   http://dx.doi.org/10.1038/75651
    - STONE, S.J.; MYERS, H.M.; WATKINS, S.M.; BROWN, B.E.; FEINGOLD, K.R.; ELIAS, P.M.; FARESE, R.V. JR, "Lipopenia and skin barrier abnormalities in DGAT2-deficient mice", J BIOL CHEM., (20031219), vol. 279, no. 12, pages 11767 - 76
    - VAN HERPEN, N.A.; SCHRAUWEN-HINDERLING, V.B., "Lipid accumulation in non-adipose tissue and lipotoxicity", PHYSIOL BEHAV, (2008), vol. 94, no. 2, doi:doi:10.1016/j.physbeh.2007.11.049, pages 231 - 41, XP022648003

DOI:   http://dx.doi.org/10.1016/j.physbeh.2007.11.049
    - YAMAZAKI, T.; SASAKI, E.; KAKINUMA, C.; YANO, T.; MIURA, S.; EZAKI, O., "Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1", JBIOL CHEM., (2005), vol. 280, no. 22, pages 21506 - 14
    - YEN, C.L.; MONETTI, M.; BURRI, B.J.; FARESE, R.V. JR., "The triacylglycerol synthesis enzyme DGAT1 also catalyzes the synthesis of diacylglycerols, waxes, and retinyl esters", J LIPID RES, (2005), vol. 46, no. 7, pages 1502 - 11
    - YEN, C.L.; STONE, S.J.; KOLIWAD, S.; HARRIS, C.; FARESE, R.V. JR., "Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis", J LIPID RES, (2008), vol. 49, no. 11, doi:doi:10.1194/jlr.R800018-JLR200, pages 2283 - 301, XP055212988

DOI:   http://dx.doi.org/10.1194/jlr.R800018-JLR200
    - ZHAO, G.; SOUERS, A.J.; VOORBACH, M.; FALLS, H.D.; DROZ, B.; BRODJIAN, S.; LAU, Y.Y.; LYENGAR, R.R.; GAO, J.; JUDD, A.S., "Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor", JMED CHEM, (2008), vol. 51, no. 3, doi:doi:10.1021/jm7013887, pages 380 - 3, XP008154453

DOI:   http://dx.doi.org/10.1021/jm7013887
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.